WE CARE FOR EXCELLENT EXPERTISE
Experienced Supervisory Board Members with a Wide Range of Expertise
The Curetis supervisory board also brings together outstanding specialist expertise in the fields of in-vitro diagnostics, life sciences and venture capital, and supports Curetis in its activities across the entire value-chain.
William E. Rhodes III - Chairman of the Supervisory Board
William E. Rhodes, III, has served as the chairman of the Supervisory Board since the IPO in 2015. Mr. Rhodes is a healthcare executive with more than 30 years of experience in the healthcare industry. During his 14-year career at Becton, Dickinson and Company (BD, 1998-2012), Mr. Rhodes held several senior leadership positions, including such roles as Worldwide President of BD Biosciences (2009-2011), a greater than US$ 1 billion revenue segment of BD. He was also an Executive Officer of BD, and was responsible for corporate strategy and merger and acquisition functions for all of BD's businesses. Furthermore, he founded BD Ventures, the venture capital arm of Becton, Dickinson and Co. Prior to Becton Dickinson, he served in senior business development positions at Johnson & Johnson and Pfizer Inc. Mr. Rhodes also served as president at The William-James Co. and has a track record of over 20 successful acquisitions and divestitures. He was director of Andor Technologies plc (2013-2014), and has served on the boards of Novocell Inc., Conticare Medical, Vitagen Inc., the California Healthcare Institute, BIO, San Jose State University Research Foundation and Silicon Valley Leadership Group. He currently serves as director of Third Day Advisors LLC (since 2013), as director of Omega Group plc (since 2013), Paramit Corporation LLC (since 2014) and Cellector Corporation (since 2015), and as a member of the Advisory Board of Cayuga Venture Fund (since 2013). Mr. Rhodes has a number of advisory roles with Cornell University, including serving on the Advisory Councils of Mc Govern Family Center of Life Sciences (since 2013) and Entrepreneurship at Cornell (since 2015). He also was appointed to the Cornell College of Agriculture and Life Sciences Dean's Council (2016) and serves as a Venture Consultant for Cornell's Blackstone Launchpad (2016). Moreover, he is on the Editorial Board of the journal Clinical and Translational Medicine. Mr. Rhodes holds a Masters degree in International Business from Seton Hall University and a BSc degree from Cornell University. He originated eleven US patents for novel topical drugs and has been a lecturer on entrepreneurship in life sciences, innovation technology and M&A at Cornell University, Seton Hall University and San Jose State University.
Mario Crovetto - Chairman of the Audit Committee
Mario Crovetto has been appointed as the chairman of the Audit Committee upon the IPO. Mr. Crovetto has been working as an independent advisor on M&A and corporate projects, notably integrations, divestments and financing since 2011. From 1999 to 2011, he was the CFO of Eurand NV (Specialty Pharmaceuticals), which he took public to NASDAQ in 2007. In the 1990 to 1999 period he held various senior business positions at Recordati (Pharmaceuticals) including VP of Corporate Development, Division Manager of Diagnostics and CFO. Prior to that he held various positions at Montedison (Speciality Chemicals), Digital Equipment Corporation, Mobil and SIAR (Management Consulting). Mr. Crovetto holds a BSc in Economics from the Università Cattolica del Sacro Cuore, Milan and a master's degree in Business Economics of Harvard University, Cambridge, MA.
DR. WERNER SCHÄFER - Vice-Chairman
Dr. Werner Schäfer has been elected Vice Chairman of the Supervisory Board upon the IPO. He is a specialist in the in-vitro diagnostics industry and has nearly 30 years of management experience in this area, having held various international management positions throughout his career – including general management, marketing and R&D at major companies such as Behringwerke/Hoechst, Abbott, Boehringer Mannheim and Roche, for example. At Boehringer and Roche, he led the laboratory systems business unit and he served as a member of the executive board at Roche Diagnostics GmbH until 2001. Since then, he has worked as a consultant and serves on various executive boards and supervisory boards in highly specialized diagnostics and medical technology companies. He was a member of the supervisory boardof BRAHMS AG (2002 to 2009, sold to Thermo Fischer), mtm laboratories AG (2003 to 2011, sold to Roche) and Vivacta Limited (2006 to 2012, sold to Novartis), Signature AG (2012 to 2013), Genomatix Software GmbH (2011 to 2013) and Cognoptix Inc. (2009 to 2014). He currently serves as a member of the advisory board of Human GmbH (since 2005), as the Chairman of the Board of Directors at ProteoMediX AG (since 2012) and as Vice-Chairman of Curetis (previously Curetis AG – since 2014). Dr. Schaefer holds a Ph.D. in Chemistry from Philipps University Marburg.
Prabhavathi Fernandes, Ph.D. - Member of the Board
Dr. Prabhavathi Fernandes has been appointed member of the Supervisory Board. Until her retirement in December 2016, she was President and Chief Executive Officer and a Member of the Board of Directors of Cempra Pharmaceuticals, a company she has founded. In 2012, she led the initial public offering and listing on Nasdaq for Cempra, and has successfully raised over half a billion dollars to date for the company. Her career of more than four decades has focused on anti-infectives, first in clinical microbiology and infectious diseases and then in pharmaceutical discovery and development. Prior to Cempra, Dr. Fernandes held executive leadership positions at pharmaceutical corporations including Bristol-Myers Squibb Pharmaceutical Research Institute, Abbott Laboratories and The Squibb Institute for Medical Research. She founded and led three biotechnology and CRO companies. She serves on the editorial board of several journals and she has authored over 250 publications and numerous reviews and book chapters.
Dr. Rudy Dekeyser - Member of the Board
Rudy Dekeyser, PhD, joined LSP in 2012. He became a Partner of the firm in that same year. Rudy’s prime focus and responsibility within LSP is to invest in unlisted securities. Prior to joining LSP, Rudy was Managing Director of VIB, the Flanders Institute for Biotechnology, which he helped establish in 1995. Under his leadership, the Institute has grown to become one of Europe’s most successful incubators in the area of life sciences. From within the Institute, several top quality companies were established and numerous business development deals were struck with large industry players. Rudy brings company building skills to the LSP team. Over the years, Rudy has been appointed a Director of many companies and has been a senior Advisor to a number of investment firms. In addition, he currently chairs the Technology Transfer Board of the prestigious European molecular biology research institute EMBL in Heidelberg, Germany. Rudy also chairs the Valorisation Board of the Dutch Genomics Initiative (NGI), assembling top researchers from sixteen research centres in The Netherlands responsible for breakthroughs in the fields of health, agriculture and food. Rudy has a Master’s degree in zoology and a PhD in molecular biology from the University of Gent.
DR. Nils Clausnitzer - Member of the Board
Dr. Nils Clausnitzer (Senior Vice President and President EMEA-APAC Lab and Distribution Services of VWR International llc./ VWR GmbH, Germany) has been elected into the Curetis Supervisory Board in June 2017. Dr. Clausnitzer has profound knowledge in sales and marketing of diagnostics and medical products. Prior to VWR International, he was President and Head of Commercial Operations, EMEA at Qiagen N.V. and General Manager for Olympus Germany. He also worked as Managing Director for Abbott Diagnostics Germany.